Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …

The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

Diabetic nephropathy (DN) is one of the most severe complications of diabetes. However,
due to its complex pathological mechanisms, no effective therapeutic methods (other than …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

Background: SGLT2 (sodium-glucose cotransporter-2) inhibitors improve heart failure–
associated outcomes in patients with type 2 diabetes. In patients with heart failure, SGLT2 …

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to
reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes …

Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …

Diabetic nephropathy (DN) is a chronic, inflammatory disease affecting millions of diabetic
patients worldwide. DN is associated with proteinuria and progressive slowing of glomerular …